NeuExcell Therapeutics Unveils Breakthrough in Stroke Treatment at ASGCT 2024
In a groundbreaking development, NeuExcell Therapeutics has revealed a significant breakthrough in its NXL-001 product for stroke treatment. The announcement was made at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, where the company...
Unraveling CRISPR Precision: BreakTag Illuminates Pathways to Improved Gene Editing
Introduction:The quest for precision in CRISPR-Cas9 gene editing takes a significant leap forward with the development of BreakTag, a method devised to enhance our understanding of DNA double-strand breaks (DSBs) induced by Cas9. This breakthrough, detailed in a...
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes– –If approved, vibegron will be the first and only beta-3 agonist for...
Herpes cure with gene editing makes progress in laboratory studies
Herpes simplex virus. Credit: CDCResearchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an...
Single-Cell Multi-Omics Analysis of IASO Bio’s Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology
SHANGHAI, NANJING, China, and SAN JOSE, Calif., May 10, 2024 /PRNewswire/ -- On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell...
Capsida Biotherapeutics to Present Preclinical Data for Parkinson’s Disease Associated with GBA Mutations Showing High Levels of GCase Enzyme Supplementation Following IV Administration
Next-generation gene therapy demonstrates best-in-class potential with majority of neurons transduced in substantia nigra and high levels of GCase supplementation after single IV infusion Broad GCase elevation achieved in NHPs, while significantly detargeting the...
WestGene’s mRNA Therapeutic Cancer Vaccine Receives FDA Approval
CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval...
Novavax Enters Co-Exclusive Licensing Agreement with Sanofi
Novavax Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include: A co-exclusive license to co-commercialize Novavax's current stand-alone...
Promising Early Results for Gene Therapy DB-OTO in Treating Genetic Deafness
Regeneron Pharmaceuticals, Inc. recently shared encouraging early results from the ongoing Phase I/II CHORD trial of DB-OTO, a gene therapy aimed at treating genetic deafness caused by variants of the otoferlin gene. The data was presented at the American Society of...
Epitor Therapeutics Unveils CasNano: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting
NEW YORK, May 9, 2024 /PRNewswire/ -- Epitor Therapeutics, a biotechnology pioneer in epigenetic editing, announces the creation of CasNano, a groundbreaking ultracompact Cas protein. CasNano, comprising less than 400 amino acids, offers an all-in-one solution for AAV...
Across two clinical trials, gene therapy restores hearing in children deaf since birth: #ASGCT24
BALTIMORE — Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday. The children who recovered their hearing are also showing improvements in their ability to speak. Some...
Bluebird bio starts 15 patients on its three multimillion-dollar gene therapies
Bluebird bio’s stock $BLUE jumped over 20% on Thursday following its first-quarter earnings release and the announcement of 15 patients starting on its three approved gene therapies: Zynteglo, Skysona and Lyfgenia. The company wrote in its financial report that 15...
Popular Services
AAV Packaging Service
AAV Analytical Service
Vector Design